Advancing Personalized Care in Rheumatoid Arthritis: A Novel Framework Using NNT, ARR, and Quality of Life Metric
This study evaluates the efficacy of monotherapy versus combination therapy in rheumatoid ar-thritis (RA) using advanced quantitative metrics such as Number Needed to Treat (NNT), Absolute Risk Reduction (ARR), Relative Risk Reduction (RRR), and Control and Experimental Event Rates (CER and EER). Th...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Romanian Association of Balneology, Editura Balneara
2025-03-01
|
| Series: | Balneo and PRM Research Journal |
| Subjects: | |
| Online Access: | https://bioclima.ro/Balneo789.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This study evaluates the efficacy of monotherapy versus combination therapy in rheumatoid ar-thritis (RA) using advanced quantitative metrics such as Number Needed to Treat (NNT), Absolute Risk Reduction (ARR), Relative Risk Reduction (RRR), and Control and Experimental Event Rates (CER and EER). The goal is to provide a structured, clinically relevant framework for op-timizing RA management and bridging the gap between clinical research and real-world appli-cation. A prospective cohort study included 160 RA patients, stratified by age, gender, and dis-ease activity. Patients received either monotherapy (MTX or LEF) or combination therapy (MTX/SSZ/HCQ). Outcomes were assessed over 24 months using statistical significance measures such as confidence intervals, t-tests, ANOVA, and non-parametric alternatives. The findings provide a direct clinical application, guiding treatment selection based on quantifiable response metrics. NNT, ARR, RRR, CER, and EER were calculated to evaluate treatment effectiveness. Combination therapy (MTX/SSZ/HCQ) demonstrated superior efficacy with an NNT of 3, compared to 25 for monotherapy. ARR and RRR were 71% and 90%, respectively, for combination therapy versus MTX/HCQ. Quality of life scores significantly improved in the combination therapy group, correlating with sustained remission over 24 months. This study presents a practical tool for clinicians by integrating longitudinal metrics and patient-specific NNT to personalize RA treatment decisions. By integrating longitudinal metrics and patient-specific NNT, it provides a novel, evidence-based approach to improving treatment outcomes in RA. |
|---|---|
| ISSN: | 2734-8458 |